公开(公告)号：US20240360090A1

公开(公告)日：2024-10-31

申请号：US18765487

申请日：2024-07-08

申请人： Milliken & Company

发明人： Wesley A. Freund ,  Innus Mohammad

IPC分类号： C07D277/82 ,  C09B29/36

CPC分类号： C07D277/82 ,  C09B29/3691

摘要： This invention relates to heterocyclic red azo colorants for seed treatment applications. The red azo colorants contain a heterocycle that includes one nitrogen atom and one sulfur atom and are free from electron-withdrawing groups on the heterocycle. Seeds for use in horticultural/agriculture applications that are coated with the heterocyclic azo colorants provide anti-counterfeiting properties to the coated seeds. A color change phenomenon is observed when the coated seeds are exposed to an acidic material, such as vinegar, and provides evidence of the authenticity of the coated seeds. The invention also relates to agricultural formulations containing the heterocyclic red azo colorants that can be used as an anti-counterfeit agents.

公开(公告)号：US20240358685A1

公开(公告)日：2024-10-31

申请号：US18766482

申请日：2024-07-08

申请人： Biohaven Therapeutics Ltd.

发明人： Jeffery Claude PELLETIER ,  Allen B. REITZ ,  Jay Edward WROBEL

IPC分类号： A61K31/428 ,  A61K45/06 ,  A61P35/00 ,  C07D277/82 ,  C07D277/84

CPC分类号： A61K31/428 ,  A61K45/06 ,  A61P35/00 ,  C07D277/82 ,  C07D277/84

摘要： Disclosed are acyl benzo[d]thiazol-2-amines having a structure according to formula (I):




including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, and complexes thereof. The compounds may be useful for the treatment of various diseases including, for example, neurological disorders such as amyotrophic lateral sclerosis, bipolar disorder, treatment resistant and major depression, general anxiety disorder, and cancers such as melanoma, breast cancer, brain cancer, and prostate cancer.

公开(公告)号：US20240327393A1

公开(公告)日：2024-10-03

申请号：US18574309

申请日：2022-07-08

申请人： SIRONAX LTD.

发明人： Jianguang HAN ,  Zhiyuan ZHANG ,  Weijie HOU ,  Yimin JIANG ,  Yanping XU

IPC分类号： C07D413/12 ,  A61K31/366 ,  A61K31/4035 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/428 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/472 ,  A61K31/496 ,  A61K31/498 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5355 ,  A61K31/536 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/5415 ,  A61K31/5513 ,  A61K31/553 ,  C07D209/46 ,  C07D217/04 ,  C07D217/06 ,  C07D263/58 ,  C07D277/82 ,  C07D279/16 ,  C07D311/18 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/08 ,  C07D498/04 ,  C07D498/08

CPC分类号： C07D413/12 ,  A61K31/366 ,  A61K31/4035 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/428 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/472 ,  A61K31/496 ,  A61K31/498 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5355 ,  A61K31/536 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/5415 ,  A61K31/5513 ,  A61K31/553 ,  C07D209/46 ,  C07D217/04 ,  C07D217/06 ,  C07D263/58 ,  C07D277/82 ,  C07D279/16 ,  C07D311/18 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/08 ,  C07D498/04 ,  C07D498/08

摘要： Provided are compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, e.g., those involving ferroptosis.

公开(公告)号：US20240253023A1

公开(公告)日：2024-08-01

申请号：US11867898

申请日：2007-10-05

申请人： Christophe Michot ,  Michel Armand ,  Michel Gauthier ,  Yves Choquette

发明人： Christophe Michot ,  Michel Armand ,  Michel Gauthier ,  Yves Choquette

IPC分类号： B01J31/02 ,  B01J31/04 ,  B01J31/06 ,  B01J31/12 ,  B01J31/18 ,  B01J31/22 ,  C07B37/02 ,  C07B37/12 ,  C07C45/46 ,  C07C45/69 ,  C07C67/00 ,  C07C255/10 ,  C07C255/17 ,  C07C255/27 ,  C07C255/46 ,  C07C255/65 ,  C07C257/14 ,  C07C311/03 ,  C07C311/04 ,  C07C311/09 ,  C07C311/48 ,  C07C317/04 ,  C07C317/08 ,  C07C317/14 ,  C07C317/22 ,  C07C317/24 ,  C07C317/34 ,  C07C317/44 ,  C07D207/452 ,  C07D213/76 ,  C07D219/10 ,  C07D231/18 ,  C07D233/90 ,  C07D239/60 ,  C07D241/42 ,  C07D249/04 ,  C07D249/10 ,  C07D249/12 ,  C07D251/70 ,  C07D277/64 ,  C07D277/82 ,  C07D285/125 ,  C07D285/135 ,  C07D285/15 ,  C07D285/16 ,  C07D303/34 ,  C07D307/54 ,  C07D307/64 ,  C07D311/52 ,  C07D311/58 ,  C07D311/82 ,  C07D319/06 ,  C07D333/16 ,  C07D333/24 ,  C07D405/06 ,  C07D409/12 ,  C07D417/10 ,  C07D417/14 ,  C07F17/02 ,  C08F4/04 ,  C08G65/334 ,  C09B69/00 ,  C09B69/02 ,  C09B69/10 ,  H01B1/12 ,  H01G9/022 ,  H01G11/02 ,  H01G11/62 ,  H01M4/00 ,  H01M4/38 ,  H01M4/58 ,  H01M4/62 ,  H01M6/00 ,  H01M6/16 ,  H01M6/18 ,  H01M10/052 ,  H01M10/0525 ,  H01M10/0565 ,  H01M10/0567 ,  H01M10/0568 ,  G02F1/1516 ,  G02F1/1523 ,  H01M4/02 ,  H01M4/131 ,  H01M4/133 ,  H01M4/134 ,  H01M4/40 ,  H01M4/48 ,  H01M4/485 ,  H01M4/505 ,  H01M4/525 ,  H01M4/60 ,  H01M4/66 ,  H01M6/04

CPC分类号： B01J31/0224 ,  B01J31/0215 ,  B01J31/0222 ,  B01J31/0225 ,  B01J31/0227 ,  B01J31/0235 ,  B01J31/0239 ,  B01J31/0247 ,  B01J31/0251 ,  B01J31/0252 ,  B01J31/0267 ,  B01J31/0271 ,  B01J31/0281 ,  B01J31/0288 ,  B01J31/0289 ,  B01J31/04 ,  B01J31/06 ,  B01J31/068 ,  B01J31/124 ,  B01J31/1815 ,  B01J31/2208 ,  C07B37/02 ,  C07B37/12 ,  C07C45/46 ,  C07C45/69 ,  C07C67/00 ,  C07C255/10 ,  C07C255/17 ,  C07C255/27 ,  C07C255/46 ,  C07C255/65 ,  C07C257/14 ,  C07C311/03 ,  C07C311/04 ,  C07C311/09 ,  C07C311/48 ,  C07C317/04 ,  C07C317/08 ,  C07C317/14 ,  C07C317/22 ,  C07C317/24 ,  C07C317/34 ,  C07C317/44 ,  C07D207/452 ,  C07D213/76 ,  C07D219/10 ,  C07D231/18 ,  C07D233/90 ,  C07D239/60 ,  C07D241/42 ,  C07D249/04 ,  C07D249/10 ,  C07D249/12 ,  C07D251/70 ,  C07D277/64 ,  C07D277/82 ,  C07D285/125 ,  C07D285/135 ,  C07D285/15 ,  C07D285/16 ,  C07D303/34 ,  C07D307/54 ,  C07D307/64 ,  C07D311/52 ,  C07D311/58 ,  C07D311/82 ,  C07D319/06 ,  C07D333/16 ,  C07D333/24 ,  C07D405/06 ,  C07D409/12 ,  C07D417/10 ,  C07D417/14 ,  C07F17/02 ,  C08F4/04 ,  C08G65/3344 ,  C09B69/00 ,  C09B69/02 ,  C09B69/10 ,  H01B1/122 ,  H01B1/128 ,  H01G9/022 ,  H01G11/02 ,  H01G11/62 ,  H01M4/00 ,  H01M4/382 ,  H01M4/5815 ,  H01M4/625 ,  H01M6/00 ,  H01M6/166 ,  H01M6/181 ,  H01M6/183 ,  H01M10/052 ,  H01M10/0525 ,  H01M10/0565 ,  H01M10/0567 ,  H01M10/0568 ,  B01J2231/122 ,  B01J2231/14 ,  B01J2231/326 ,  B01J2231/341 ,  B01J2231/348 ,  B01J2231/4205 ,  B01J2231/543 ,  B01J2531/35 ,  B01J2531/824 ,  C07C2601/10 ,  C07C2602/42 ,  G02F2001/1518 ,  G02F1/1525 ,  H01M4/02 ,  H01M4/131 ,  H01M4/133 ,  H01M4/134 ,  H01M4/405 ,  H01M4/48 ,  H01M4/485 ,  H01M4/505 ,  H01M4/525 ,  H01M4/5825 ,  H01M4/60 ,  H01M4/661 ,  H01M6/04 ,  H01M6/164 ,  H01M6/168 ,  Y02E60/13 ,  Y10S430/127 ,  Y10T29/49108 ,  Y10T428/2918

摘要： The invention concerns ionic compounds in which the anionic load has been delocalized. A compound disclosed by the invention is comprised of an amide or one of its salts, including an anionic portion combined with at least one cationic portion M+m in sufficient numbers to ensure overall electronic neutrality; the compound is further comprised of M as a hydroxonium, a nitrosonium NO+, an ammonium —NH4+, a metallic cation with the valence m, an organic cation with the valence m, or an organometallic cation with the valence m. The anionic portion matches the formula RF—SOx—N−Z, where RF is a perflourinated group, x is 1 or 3, and Z is an electroattractive substituent. The compounds can be used notably for ionic conducting materials, electronic conducting materials, colorants and the catalysis of various chemical reactions.

公开(公告)号：US20240199562A1

公开(公告)日：2024-06-20

申请号：US18286569

申请日：2022-04-14

申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE ,  UNIVERSITÉ COTE D’AZUR ,  INSTITUT CURIE

发明人： MAEVA DUFIES ,  GILLES PAGES ,  CYRIL RONCO ,  RACHID BENHIDA

IPC分类号： C07D277/82 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/428 ,  A61P35/00 ,  C07D235/30 ,  C07D263/58

CPC分类号： C07D277/82 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/428 ,  A61P35/00 ,  C07D235/30 ,  C07D263/58

摘要： The present invention relates to ureal derivatives of formula (I) and pharmaceutical compositions comprising such derivatives for use in the treatment of uveal melanoma.

公开(公告)号：US12005047B2

公开(公告)日：2024-06-11

申请号：US18361837

申请日：2023-07-29

申请人： Biohaven Therapeutics Ltd.

发明人： Jay Edward Wrobel ,  Allen B. Reitz ,  Jeffery Claude Pelletier ,  Garry Robert Smith ,  Haiyan Bian

IPC分类号： A61K31/428 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K31/454 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K38/05 ,  A61K38/06 ,  A61K39/00 ,  A61K45/06 ,  A61P25/00 ,  A61P25/28 ,  A61P35/00 ,  C07D277/82 ,  C07D417/12 ,  C07K5/062 ,  C07K5/083 ,  C07K5/087

CPC分类号： A61K31/428 ,  A61K9/006 ,  A61K9/1617 ,  A61K9/2004 ,  A61K31/454 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K38/05 ,  A61K38/06 ,  A61K39/4636 ,  A61K45/06 ,  A61P25/00 ,  A61P25/28 ,  A61P35/00 ,  C07D277/82 ,  C07D417/12 ,  C07K5/06026 ,  C07K5/0806 ,  C07K5/0808 ,  C07K5/0812 ,  A61K2300/00

摘要： Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

公开(公告)号：US20240158402A1

公开(公告)日：2024-05-16

申请号：US18393556

申请日：2023-12-21

申请人： NOVITA PHARMACEUTICALS, INC. ,  CORNELL UNIVERSITY

发明人： Xin-Yun Huang ,  Christy Young Shue

IPC分类号： C07D487/04 ,  A61K31/428 ,  A61K31/433 ,  A61K31/522 ,  C07D249/12 ,  C07D277/82 ,  C07D285/08 ,  C07D405/12

CPC分类号： C07D487/04 ,  A61K31/428 ,  A61K31/433 ,  A61K31/522 ,  C07D249/12 ,  C07D277/82 ,  C07D285/08 ,  C07D405/12

摘要： Provided are compositions and methods for treating a condition or disorder mediated by fascin activity in a subject in need thereof which method comprises administering to the subject a therapeutically effective amount of at least one compound of any one of Formula I-a to I-n, II, II-a, II-b or III or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240091205A1

公开(公告)日：2024-03-21

申请号：US18361836

申请日：2023-07-29

申请人： Biohaven Therapeutics Ltd.

发明人： Jay Edward WROBEL ,  Allen B. REITZ ,  Jeffery Claude PELLETIER ,  Garry Robert SMITH ,  Haiyan BIAN

IPC分类号： A61K31/428 ,  A61P25/00 ,  A61P25/28 ,  A61K38/06 ,  C07K5/083 ,  C07K5/087 ,  C07D277/82 ,  A61K31/454 ,  A61K31/496 ,  A61K31/5377 ,  A61K38/05 ,  A61K45/06 ,  C07D417/12 ,  C07K5/062 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20

CPC分类号： A61K31/428 ,  A61P25/00 ,  A61P25/28 ,  A61K38/06 ,  C07K5/0806 ,  C07K5/0808 ,  C07K5/0812 ,  C07D277/82 ,  A61K31/454 ,  A61K31/496 ,  A61K31/5377 ,  A61K38/05 ,  A61K45/06 ,  C07D417/12 ,  C07K5/06026 ,  A61K9/006 ,  A61K9/1617 ,  A61K9/2004 ,  A61K2300/00 ,  A61K9/0056 ,  A61K9/2018 ,  A61K9/2063 ,  A61K9/485

摘要： Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

公开(公告)号：US11866440B2

公开(公告)日：2024-01-09

申请号：US17160948

申请日：2021-01-28

申请人： NOVITA PHARMACEUTICALS, INC. ,  CORNELL UNIVERSITY

发明人： Xin-Yun Huang ,  Christy Young Shue

IPC分类号： C07D487/04 ,  C07D405/12 ,  C07D277/82 ,  C07D285/08 ,  C07D249/12 ,  A61K31/428 ,  A61K31/433 ,  A61K31/522

CPC分类号： C07D487/04 ,  A61K31/428 ,  A61K31/433 ,  A61K31/522 ,  C07D249/12 ,  C07D277/82 ,  C07D285/08 ,  C07D405/12

摘要： Provided are compositions and methods for treating a condition or disorder mediated by fascin activity in a subject in need thereof which method comprises administering to the subject a therapeutically effective amount of at least one compound of any one of Formula I-a to I-n, II, II-a, II-b or III or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230381150A1

公开(公告)日：2023-11-30

申请号：US18361838

申请日：2023-07-29

申请人： Biohaven Therapeutics Ltd.

发明人： Jay Edward WROBEL ,  Allen B. REITZ ,  Jeffery Claude PELLETIER ,  Garry Robert SMITH ,  Haiyan BIAN

IPC分类号： A61K31/428 ,  A61P25/00 ,  A61P25/28 ,  A61K38/06 ,  C07K5/083 ,  C07K5/087 ,  C07D277/82 ,  A61K31/454 ,  A61K31/496 ,  A61K31/5377 ,  A61K38/05 ,  A61K45/06 ,  C07D417/12 ,  C07K5/062 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20

CPC分类号： A61K31/428 ,  A61P25/00 ,  A61P25/28 ,  A61K38/06 ,  C07K5/0806 ,  C07K5/0808 ,  C07K5/0812 ,  C07D277/82 ,  A61K31/454 ,  A61K31/496 ,  A61K31/5377 ,  A61K38/05 ,  A61K45/06 ,  C07D417/12 ,  C07K5/06026 ,  A61K9/006 ,  A61K9/1617 ,  A61K9/2004 ,  A61K2300/00

摘要： Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.